ArticleLeukemia research2018

A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease.

Kendra Sweet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.